Tumor cells with downregulated expression of YB-1 exhibit enhanced sensitivity to irradiation and anti-cancer drugs [42,49], suggesting that targeting YB-1 by RNA interference in combination with chemotherapy and/or radiotherapy may potentiate the therapeutic effects in tumor patients. Here, YBX1 is linked to neoplasm.